You searched for "lid"
Stem cell therapy for Parkinson’s disease: researching for an effective cure
1 December 2015
| Romina Vuono
|
EYE - Neuro-ophthalmology
Neurodegenerative diseases are characterised by the chronic and progressive loss of neurons, which in turn results in loss of cognitive and physical functions. The World Health Organization has estimated that the disability-adjusted life years lost from neurological disease was about...
Nano-ophthalmology paves a new path in the future of eyecare
1 December 2022
| Stylianos Mastronikolis, Jayasis Bandyopadhyay
|
EYE - General
Introduction The treatments of ocular conditions in the field of ophthalmology varies from topical to surgical procedures. The field of nanotechnology is one of the fast-growing fields of medicine, which plays an important role in turning the impossibilities of the...
XXII SARCS (State of the Art Refractive Cataract Surgery) Symposium 2024
14 June 2024
by Andrew Bourne, BSc, MCOptom, DipTp(IP), Dip Glauc, Principal Optometrist, Hull & East Yorkshire Eye Hospital, UK. Once again, Milind Pande welcomed over 220 ophthalmologists and allied professionals to his annual symposium, this year held once again at the University...
UK Eye Genetics Group Annual Conference
9 June 2023
by Chloe M. Stanton, UK-EGG Treasurer, MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh Delegates including ophthalmic clinicians, clinical geneticists, genetic counsellors and research scientists travelled to Edinburgh from across the UK and Europe to attend...
Informed consent in ophthalmology care in the UK: A critical component of patient‑centred practice
2 April 2025
| Ali Yagan
|
EYE - General
Informed consent is a cornerstone of ethical and legal practice in healthcare, particularly in fields like ophthalmology where specialised interventions can have significant implications for a patient’s vision and quality of life. In the UK, informed consent is not merely...
Minimally Invasive Glaucoma Surgery – A Practical Guide
1 October 2017
| Indira Madgula
|
EYE - Glaucoma
The treatment of patients with mild to moderate glaucoma has evolved rapidly in the last decade. Traditionally, medical and laser treatments were the mainstay of therapy for this group of patients. Trabeculectomy, non-penetrating surgery and glaucoma drainage implants were reserved...
Phacoemulsification Cataract Surgery
The book, through a ‘rear-ended’ approach to training, covers basic and fundamental skills for the novice ophthalmic surgeon embarking on phacoemulsification cataract surgery. As the preface states, this is a ‘key surgical technique for an ophthalmologist to learn’. However, achieving...New Treatments in Noninfectious Uveitis
As a specialist registrar training in Aberdeen there were two important lessons I learned which have proved to be invaluable over the years for two very different reasons. The first lesson learned was to never underestimate the wind chill factor...Does vitrectomy increase the risk of glaucoma? A retrospective review from a UK hospital
5 April 2022
| Aiman Jamal, Helen Burn, Asifa Shaikh
|
EYE - Glaucoma, EYE - Vitreo-Retinal, EYE - General
The authors investigate what proportion of patients undergoing pars plana vitrectomy subsequently developed ocular hypertension or a diagnosis of glaucoma. A systematic review carried out in 2017 including seven studies found that there is evidence that pars plana vitrectomy (PPV)...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...